Metabolism and Disposition of a Selective α₇ Nicotinic Acetylcholine Receptor Agonist in Humans

Abstract

ABSTRACT:The The formation of 2 was found to be mediated by CYP2D6, a polymorphically expressed enzyme absent in 5 to 10% of white people, whereas the generation of 4 was catalyzed by CYP2D6, FADcontaining monooxygenase 1 (FMO1), and FMO3. It is of interest that, although no overall gender-related differences in excretory routes, mass recoveries, pharmacokinetics, or metabolite profiles of 1 were evident, the observation of one of eight subjects (13%) showing disparate (relative to all other volunteers) systemic exposures to 1, and urinary and plasma quantitative profiles nearly devoid of 2 with the highest levels of 1, seem consistent with both the identification of CYP2D6 as the only major recombinant cytochrome P450 transforming 1 to 2 and the demographics of white CYP2D6 poor metabolizers. Data also reported herein suggest that 4 is generated predominantly by renal FMO1 in humans.

Metabolism and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor Apatinib in Humans

“…However, there are a few prior examples of CYP2D6-mediated formation of N-oxide. Procainamide (Lessard et al, 1999), sparteine , citalopram (Olesen et al, 1999) (Shaffer et al, 2007) probably are the only limited number of compounds reported previously to have N-oxidation catalyzed by CYP2D6.…”

The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia

“…PHA-543613 and PHA-568487 exhibited sufficient preclinical efficacy and safety to support their advancement into phase I single-ascendingdose and multiple-ascending-dose safety, tolerability and pharmacokinetic studies. PHA-543613 also demonstrated a linear pharmacokinetic profile and a desirable half-life in human subjects (approximately 9-12 h) [79]. CogState battery testing of PHA-543613 and PHA-568487 revealed a modest improvement in cognitive function at low doses of 6 mg twice a day; however, a low frequency of cardiovascular arrhythmia with no evidence of QTc prolongation or other electrocardiographic interval changes was also observed in these studies.…”

Alpha-7 nicotinic acetylcholine receptor agonists in intracerebral hemorrhage: an evaluation of the current evidence for a novel therapeutic agent

“…6,22,32,42 Furthermore, although the optimal timing of drug administration is not currently known, the preclinical data support postictus drug administration. In particular, in the study described above, Hijioka et al administered PNU-282987 at different initial time points relative to ICH onset (1 hour prior, and 3, 6, and 12 hours after), and demonstrated a time-dependent decline in efficacy that remained statistically significant until 6 hours after ICH onset, with the greatest efficacy being observed with initial dosing at 3 hours after ICH onset.…”